-
公开(公告)号：US20240350425A1
公开(公告)日：2024-10-24
申请号：US18651552
申请日：2024-04-30
申请人： NOVALIQ GMBH
CPC分类号： A61K31/02 , A61K9/0048 , A61K47/06
摘要： The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.
-
公开(公告)号：US20200206241A1
公开(公告)日：2020-07-02
申请号：US16731824
申请日：2019-12-31
申请人： NOVALIQ GMBH
IPC分类号： A61K31/5575 , A61K47/06 , A61K9/08 , A61K9/00
摘要： The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.
-
公开(公告)号：US20190224123A1
公开(公告)日：2019-07-25
申请号：US16259037
申请日：2019-01-28
申请人： NOVALIQ GMBH
摘要： The invention provides liquid compositions in the form of physically stable emulsions comprising a semifluorinated alkane. The semifluorinated alkane is comprised in the dispersed phase, which may also include an active pharmaceutical ingredient. One of the preferred active ingredients is propofol. The compositions are optionally heat sterilisable and can be used for pharmaceutical or cosmetic product applications, and administered topically, intravenously, or via other routes.
-
公开(公告)号：US20180326066A1
公开(公告)日：2018-11-15
申请号：US16041317
申请日：2018-07-20
申请人： Novaliq GmbH
IPC分类号： A61K47/06 , A61K31/02 , A61K31/11 , A61K31/436 , A61K9/08 , A61K9/00 , A61K45/06 , A61K31/07 , A61K31/202 , A61K31/203 , A61K31/232 , A61K31/4418
摘要： The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.
-
公开(公告)号：US20230330056A1
公开(公告)日：2023-10-19
申请号：US18156749
申请日：2023-01-19
申请人： Novaliq GmbH
IPC分类号： A61K31/351 , A61K45/06 , A61K9/00 , A61K9/08 , A61K31/436 , A61K31/07 , A61K31/11 , A61K31/202 , A61K31/203 , A61K31/232 , A61K31/4418 , C09K15/00 , C08F14/26 , A61K47/06 , A61K31/02
CPC分类号： A61K31/351 , A61K45/06 , A61K9/0048 , A61K9/08 , A61K31/436 , A61K31/07 , A61K31/11 , A61K31/202 , A61K31/203 , A61K31/232 , A61K31/4418 , C09K15/00 , C08F14/26 , A61K47/06 , A61K31/02 , A61P27/02
摘要： The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.
-
公开(公告)号：US20230139672A1
公开(公告)日：2023-05-04
申请号：US18146306
申请日：2022-12-23
申请人： NOVALIQ GMBH
摘要： The invention provides liquid compositions in the form of physically stable emulsions comprising a semifluorinated alkane. The semifluorinated alkane is comprised in the dispersed phase, which may also include an active pharmaceutical ingredient. One of the preferred active ingredients is propofol. The compositions are optionally heat sterilisable and can be used for pharmaceutical or cosmetic product applications, and administered topically, intravenously, or via other routes.
-
公开(公告)号：US20210100904A1
公开(公告)日：2021-04-08
申请号：US17072923
申请日：2020-10-16
申请人： NOVALIQ GMBH
IPC分类号： A61K45/06 , A61K9/08 , A61K31/355 , A61K9/00 , A61K9/107 , A61K47/06 , A61K31/436
摘要： The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.
-
公开(公告)号：US20200246463A1
公开(公告)日：2020-08-06
申请号：US16783972
申请日：2020-02-06
申请人： Novaliq GmbH
IPC分类号： A61K47/06 , A61K31/02 , A61K31/4418 , A61K31/232 , A61K31/203 , A61K31/202 , A61K31/11 , A61K31/07 , A61K31/436 , A61K9/08 , A61K9/00 , A61K45/06
摘要： The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.014 秒)
